This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Pancreatic ductal adenocarcinoma (PDAC) is the most life-threating disease among all digestive system malignancies. We developed a blood mRNA PDAC screening system using real-time detection PCR to detect the expression of 56 genes, to discriminate PDAC from noncancer subjects. We undertook a clinical study to assess the performance of the developed system. We collected whole blood RNA from 53 PDAC patients, 102 noncancer subjects, 22 patients with chronic pancreatitis, and 23 patients with intraductal papillary mucinous neoplasms in a per protocol analysis.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma is among the most difficult malignancies to diagnose and treat, resulting in poor prognosis. 1, 2 Approximately 10% of PDAC patients are diagnosed in an early phase (ie, stage I and II), when radical treatment involving surgical removal of the PDAC lesions is available. 3, 4 Chemotherapy has only limited efficacy in terms of prolonging the survival of PDAC patients. 5 The overall survival after diagnosis of PDAC is less than 5 years, which is the poorest among all digestive system malignancies. Therefore, novel diagnostic tools capable of detecting PDAC in the early stages, as well as sufficiently effective treatment options to substantially improve the prognosis of PDAC, are required.
Previously, we reported that the gene expression profile of peripheral blood showed characteristic alterations in the digestive system of cancer patients. 6 The local cancer tissues of PDAC were substantially infiltrated with inflammatory cells, including immune-suppressing cells as well as lymphocytes expressing the immune checkpoint molecule, programmed cell death 1 (PD-1). In addition, certain genes expressed in whole peripheral blood, as well as CD4 + cells and CD14 + cells, were found to be important in the inflammation seen in PDAC. 7 Therefore, peripheral blood cells reflect the host inflammatory condition in association with local cancer tissues in PDAC.
We developed a blood mRNA PDAC screening system based on determining changes in the mRNA expression levels of 56 genes in whole blood by RTD-PCR. We undertook a multi-institutional clinical study to test the performance of this system. The system performance was assessed in 53 PDAC patients, 102 noncancer subjects, 22 chronic pancreatitis patients, and 23 IPMN patients. The system showed sensitivity of 73.6% (95% CI, 59.7%-84.7%). The specificity for noncancer volunteers, chronic pancreatitis patients, and IPMN patients was 64.7% (54.6%-73.9%), 63.6% (40.7%-82.8%), and 47.8%
(26.8%-69.4%), respectively. Thus, the screening system, based on examination of changes in gene expression in blood, could be useful.
| MATERIAL S AND ME THODS

| Complementary DNA microarray analysis to determine gene expression in whole blood
Twenty-eight PDAC patients and 27 noncancer subjects (Table S1) were enrolled for gene expression analysis of whole blood cells, to select candidate genes for establishing a blood PDAC screening system.
For blood collection, we used PAXgene blood RNA tubes (PreAnalytix, Hombrechtikon, Switzerland) in which the RNA of whole blood cells was immediately stabilized after collection and mixed with reagents in the tubes. The study was approved by the Institutional Review Board of Kanazawa University (Kanazawa, Japan) and its related hospitals.
We used a cDNA microarray Whole Human Genome 4× 44K Array kit (G4112F; Agilent Technologies, Santa Clara, CA, USA) for analysis of gene expression of whole blood obtained from 17 PDAC patients and 13 noncancer subjects, as described previously. 7 Briefly, RNA was extracted from PAXgene blood RNA tubes using a PAXgene Blood RNA System kit (PreAnalytix) in accordance with the manufacturer's protocol, followed by RNA quantification using a NanoDrop ND-1000
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Cy-3-labeled cRNA was synthesized from 300 ng total RNA using a Quick Amp Labeling kit, and then hybridized to the cDNA microarray. The hybridized microarray was scanned using a cDNA Microarray Scanner (Model G2505B; Agilent Technologies), and the obtained image was processed using Feature Extraction software version 9.5.3.1 (Agilent Technologies) to obtain the value data. The data, which were normalized using GeneSpring GX software version 11.0.2 (Agilent Technologies), were used to select candidate genes for RTD-PCR analysis. The cDNA microarray data were deposited in Gene Expression
Omnibus (NBCI, Bethesda, MD, USA) with the number GSE125158.
| Real-time detection PCR
Gene expression analysis by RTD-PCR for candidate genes selected from cDNA microarray data was undertaken as described previously. 7 Briefly, cDNA was synthesized from total RNA extracted from samples in PAXgene Blood RNA tubes using an RT 2 HT First Strand Kit (Qiagen, Hilden, Germany). Synthesized cDNA was measured using Custom RT 2 Profiler PCR Arrays (Qiagen) according to the manufacturer's instructions. Quantitative PCR was carried out using a LightCycler 480 Instrument II version 1.5.0.39 (Roche, Basel, Switzerland).
| Selection of genes for blood mRNA screening system
To establish the mRNA blood screening system, we used blood RNA from 28 PDAC patients and 27 noncancer subjects. Using RTD-PCR, sensitivity of this system for both stage I and stage II PDAC was 78.6% (57.1%-100%),
suggesting that detection of PDAC by the system is not dependent on the stage of PDAC. These results indicated that the screening system, relying on assessment of changes in mRNA expression in blood cells, is a viable alternative screening strategy for PDAC.
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clinical trial, in vitro diagnostics, mRNA screening system, pancreas cancer, whole blood cells we measured the mRNA expression levels of candidate genes whose expression was assessed by cDNA microarray. For the selection of genes, we used a support vector machine with the linear kernel and sequential variable erasing methods. 8 Discrimination between PDAC and noncancer subjects was undertaken using Fisher's linear discriminant with a penalized matrix for gene expression correlation analysis. We applied leave-one-out cross-validation, using the RTD-PCR data of 1 case as a test dataset for both gene selection and classifier building. Discrimination ability was assessed according to the sensitivity and specificity. The number of genes used for classification was based on cross-validated sensitivity and specificity. Finally, we developed a final classifier by applying the whole algorithm with the determined number of genes to all 55 cases to be mounted in the blood mRNA screening system.
| Clinical study design to assess performance of blood mRNA screening system
The clinical study to test the system performance was designed in consultation with the Japanese Pharmaceutical and Medical Device Agency, which is a Japanese regulatory agency, working together with the Ministry of Health, Labour, and Welfare to protect public health by assuring the safety, efficacy, and quality of pharmaceuticals and medical devices, and was approved by each participating institutional ethical committee (UMIN000020758). The primary end-points were sensitivity and specificity of the blood mRNA PDAC screening system. The secondary end-points were the PPV and NPV for the blood mRNA PDAC screening system, and the sensitivity, specificity, PPV, and NPV for CEA and CA19-9. The clinical study was undertaken in 50 PDAC patients and 100 noncancer subjects. We also enrolled patients with IPMN and chronic pancreatitis, whose clinical data were not available. The inclusion criteria were as follows: PDAC patients, diagnosis by imaging studies or pathologically; chronic pancreatitis and IPMN patients, diagnosis by imaging studies; and non-cancer subjects, considered normal based on medical records for the previous year or on current medical check-up. The subjects were aged between 40 and 90 years. All subjects provided written informed consent prior to participating in the study. Exclusion criteria are shown in Blood was collected using PAXgene blood RNA tubes (PreAnalytiX) for mRNA expression measurement. Sera were also collected for CEA and CA19-9 measurement by the standard chemiluminescent enzyme immunoassay. Results of CEA greater than 5.0 ng/mL and CA19-9 greater than 37.0 U/mL were judged to be positive.
| Statistical analysis
For the clinical validation study, we used Wilcoxon's signed-rank test or Fisher's exact test for group comparisons. In evaluating the system performance, point estimates and 95% CIs of sensitivity and specificity were calculated. Pearson's correlation analysis and t test were applied using IBM SPSS Statistics (IBM, Armonk, NY, USA).
| RE SULTS
| Establishment of blood PDAC screening system
We reported previously that the gene expression profile of whole blood cells from the digestive system of cancer patients was different from that of normal noncancer subjects. 6 Based on these findings, we established a blood PDAC screening system using RTD-PCR for genes, the expression levels of which in whole blood were altered in PDAC patients. We first extracted 2 sets of 384 genes assessing the cDNA microarray data of 17 PDAC patients and 13 noncancer subjects (GSE125158). The 384 genes in 1 set were selected by their expression, which was affected at FC >1.5
and P < 0.00013. The other set of 384 genes was selected by a powerful machine learning algorithms-random forest method, 9 in which 200 bootstraps were used to find the top genes that have more power to distinguish PDAC from noncancer subjects. The 179 genes that were included in both gene sets were finally selected. From the remaining genes in this analysis, we chose 134 genes, considering their biological meanings. We also selected 51 genes, whose flags for expression were positive in 12 of 17 PDAC patients and absent in 10 of 13 noncancer subjects. Thus, we finally selected 364 genes to further construct the equation for the PDAC screening system ( Figure S1 ). For 28 PDAC patients and 27 noncancer subjects, including the above subjects, we carried out RTD-PCR of these 364 genes and 17 housekeeping genes including GAPDH (Table S3 ). We used GAPDH as a reference as its expression was substantial and showed no difference between PDAC patients and noncancer subjects. Therefore, we have used delta Cp, which was obtained by subtraction of the GAPDH Cp value from that of each gene, for mRNA expression. To determine the gene number for discrimination of PDAC and noncancer subjects, we used the statistical method applied with the support vector machine and recursive feature elimination 8 during the leave-one-out cross-validation among these 55 cases ( Figure S2 ).
The cross-validated sensitivity and specificity to discriminate PDAC from noncancer subjects were sufficiently high (93% and 100%, respectively) based on 56 genes; increasing the number of genes above 56 did not increase discrimination performance. By this analysis, we found that 56 genes were sufficient for the most excellent accuracy. 
Therefore, we finally selected 56 genes (Table 1) for expression analysis in whole blood cells in 28 PDAC and 27 noncancer subjects.
As a final classifier, obtained through application of the classification algorithm based on 56 genes to all 55 subjects, we obtained the following equation for PDAC diagnosis using the weighted linear sum of each gene's expression level:
In the formula above, a n is a coefficient value for each gene (Table 1) ; "a1*gene 1 + a2*gene 2 + ……… + a56**gene 56" was determined based on Fisher's linear discriminant, and its threshold was 209.018. To simplify the threshold value as zero by the formula, intercept value, −209.018, in the equation, was mounted. Thus, sum-values 0 or higher and less than 0 were taken as positive and negative for PDAC, respectively.
| Characteristics of subjects registered in the clinical study used to assess the performance of blood mRNA screening system
We designed a clinical study to assess the performance of the blood mRNA screening system. The study cohort consisted of 54 patients with PDAC, 25 with IPMN, 22 with chronic pancreatitis, and 104 noncancer subjects ( Figure 1 ). All subjects were assessed for suitability for the safety analysis cohort and full analysis set. After applying the exclusion criteria, we finally included 53 patients with PDAC, 23 with IPMN, 22 with chronic pancreatitis, and 102 noncancer subjects.
Some of the clinical characteristics, such as age, gender, and body mass index, were different between PDAC patients and noncancer subjects ( Table 2 ). The frequency of alcohol drinking was not different between PDAC patients and noncancer subjects ( Table 2 ).
| Performance of blood mRNA screening system
The sensitivity and specificity of the blood mRNA PDAC screening system for 53 PDAC patients and 102 noncancer subjects was 73.6%
(95% CI, 59.7%-84.7%) and 64.7% (54.6%-73.9%), respectively. The specificity for chronic pancreatitis and IPMN patients was 63.6%
(95% CI, 40.7%-82.8%) and 47.8% (95% CI, 26.8%-69.4%), respectively ( Table 3 ). The sensitivity for the conventional tumor markers CEA and CA19-9 was 41.5% (95% CI, 28.1%-55.9%) and 71.7% (95% CI, 57.7%-83.2%), respectively (Tables 4 and 5 ). In noncancer subjects, the specificity for CEA and CA19-9 was 96.1% (95% CI, 90.3%-98.9%) and 97.1% (95% CI, 91.6%-99.4%), respectively (Tables 4 and   5 ). The PPVs of the mRNA blood screening system, CEA, and CA19-9
for chronic pancreatitis and IPMN were 76.5%-83.0%, 71.9%, and 95.1%, respectively (Tables 3-5) ; the respective values for noncancer subjects were 50.6%, 82.1%, and 92.9%, respectively. The NPVs of the mRNA blood screening system, CEA, and CA19-9 for all cases were 86.1%, 81.1%, and 90.4%, respectively (Tables 3-5 TA B L E 1 (Continued) markers and scores of the mRNA screening system. The correlation coefficients for CEA and CA19-9 with scores of the mRNA screening system were 0.072 and 0.14, respectively, with P-values of .308 and .048, respectively. These results indicate no correlation between CEA and the mRNA screening system, and very weak correlation between CA19-9 and the mRNA screening system (Figure 2 ).
Regarding disease stages, the blood mRNA screening system showed a sensitivity of 78.6% for stages I and II, and a similar value of 71.8% for stages III and IV (Table 6 ).
| Clinical characteristics and blood mRNA screening system
In terms of clinical parameters and sum-values of the blood mRNA screening system, we applied correlation analyses for continuous data (age, height, and body weight) and t tests for category data (gender, body weight loss of more than 5 kg over 6 months, smoking, alcohol drinking, and familial history of PDAC) with sum-values of the blood mRNA screening system (Table S4 ). Although the P value for the age correlation analysis was less than .05, correlation efficiency was weak (0.145). Average values of the sum-values of the blood mRNA screening system for nonsmoker and current smoker were significantly different (P = .047), but both values were less than zero. Although the sum-value of past drinker was significantly higher than those of nondrinker and current drinker (P = .045 and P = .043, respectively), the sum-value for the current drinker was not higher than current drinker or nondrinker.
| D ISCUSS I ON
In this study, we developed a blood mRNA PDAC screening system measuring the expression of 56 genes in whole blood by RTD-PCR, followed by weighted linear summation. We undertook a multicenter clinical study to validate the performance of this blood mRNA screening system for PDAC detection, by gene expression analysis using RTD-PCR. This system showed that sensitivity was 73.6% and the specificity for healthy subjects was 64.7%.
The principle of this system is unique, being based on changes in gene expression in the peripheral blood. 6, 7, 10, 11 Previously, we reported that PDAC is related to inflammatory changes in local tumor tissue, as well in peripheral blood. 7,10 Therefore, we assumed that alterations in the gene expression profile in the peripheral blood of PDAC patients would be associated with systemic inflammatory responses of the host. Based on this principle, we selected genes that showed differences in expression between the whole blood from PDAC patients and noncancer subjects.
The prognosis of PDAC is extremely poor due to in part to difficulty of diagnosis in the early stages. 12 At present, there is no definitive screening method for PDAC, and various methods are used clinically, including ultrasonography and computed tomography, for imaging-based diagnosis and determination of tumor markers in blood. 13 With regard to blood test tumor markers, CA19-9, 14 Span-1, 15 CA50, CA242, DUPAN-2, and TAG-72 [16] [17] [18] are categorized as glucose-chain antigens; CEA is an embryonic antigen 19 that is typically present in high levels in PDAC, although not in all cases. In addition to these conventional tumor markers, a new approach has been developed using excreted small particles, called exosomes; these are believed to include molecules specific for cancers, 20 although the analysis methods are still under development.
As diagnosis of PDAC in the early stages is extremely rare, there are insufficient data regarding the performance of the mRNA screening system for early-stage PDAC. The PDAC patients in this study were mainly in advanced stages (ie, III or IV); only 14 patients were in stage I or II. The sensitivity of the mRNA F I G U R E 1 Outline of the clinical study to assess the performance of the blood mRNA screening system for pancreatic ductular adenocarcinoma (PDAC screening system for these PDAC patients was 78.6%, illustrating the potential benefit of this system for early detection of PDAC.
We previously disclosed that PDAC local tissues were associated with inflammation, even if they were still small. 7 Thus, the high sensitivity of the mRNA screening system, capable of detecting PDAC in early stages, might be an important beneficial feature, one that has proven difficult using other conventional tumor marker systems. Based on this previous study, the principle of the mRNA screening system relies on gene expression alteration of peripheral blood cells affected by development of PDAC. This is the feature that distinguishes the system from conventional tumor markers (ie, CEA and CA19-9), which are produced by cancer tissues. In this context, the novel mRNA system would be a useful screening method as the examination involves a blood test, which can be undertaken without the need for specific medical devices and is minimally invasive.
The establishment of a PDAC screening algorithm requires further development, including the novel blood mRNA screening system described herein, along with other tumor markers and diagnostic imaging tools. 21 Although ultrasonography is noninvasive,
it cannot be used to determine dilatation of the pancreatic duct or tumorous lesions in the pancreas; therefore, patients also require endoscopy, 22 computed tomography, and MRI examinations. 23 As discussed above, conventional tumor markers are not sufficient for screening for PDAC in the early stages, which could allow the disease to be cured by surgery.
The genes included in this system were selected biostatistically, based on changes in their expression levels in the whole blood of PDAC patients forming a different cohort from that of the clinical study. The mechanisms by which these genes are affected in PDAC are intriguing; some genes are involved in immunological processes, consistent with the previous finding that PDAC is associated with both local and systemic immune reactions. 7 Further investigations to determine the biological significance of these genes will provide insight into the immunopathological features of PDAC, leading to further development of diagnostic tools as well as immunological treatments for the disease.
In conclusion, we developed a novel in vitro diagnostic system based on assessment of the host immune response to PDAC. As it remains unclear how this novel system should best be used as an adjunct to conventional PDAC diagnostic or screening systems, further investigations to improve the PDAC screening algorithm, including our novel screening system, should be undertaken to improve the prognosis of PDAC patients by diagnosis in the early stages of disease progression.
